1.Effects of genistein on PCNA expression and cell cycle in human hypertrophic scar fibroblasts in vitro
Chuan CAO ; Shirong LI ; Heng YAO ; Zhi FENG ; Xia DAI ; Yanqing CHEN ; Xiaoge LI ; Liang CHEN
Chinese Journal of Medical Aesthetics and Cosmetology 2008;14(3):159-162
Objective To observe the effects of genistein on PCNA expression and cell cycle in fibroblasts derived from human hypertrophic scar in order to explore the mechanism of its inhibition on hypertrophic scar (HS) fibroblast proliferation. Methods The human hypertrophic scar fibroblasts were cultured in vitro. Genistein with various concentrations (25, 50, 100 μmol/L) was co-cultured in the medium for 48 hours. The expression of PCNA was detected with immunocytochemical staining method and the cell cycle was measured with flow cytometry. Results Genistein could significantly decrease PCNA expression in HS fibroblasts, especially when its concentration at 50 μmol/L or 100 μmol/L. The cell percentage of G0~G1 phase decreased with drug′s concentration, and G2~M percentage increased conversely, implying the suspension of mitosis. In 100 μmol/L group, most cells blocked at S phase and a hypodiploid apoptosis peak could be observed ahead of G1 phase. Conclusion Genistein can inhibit the proliferation of human hypertrophic scar by blocking cell division as well as decreasing DNA synthesis.
2.Studies on Shedding Virus and the Formation of Aerosol of H_9N_2 Subtype AIV
Yong-Zhi CAO ; Wei-Ming MA ; Xiao-Xia LI ; Tong-Jie CHAI ; Hai-Yan ZHANG ;
Microbiology 2008;0(10):-
In order to study the regularity of shedding virus from infected SPF chickens and the formation of aerosol of H9N2 subtype AIV, SPF chickens were bred in a positive and negative pressure isolator. Aerosol samples were collected by AGI-30 (All Glass Impinger-30) extractor, and simultaneously trachea and cloaca samples were collected by tracheal swabs and cloacal swabs in different periods after challenged with vi- ruses. The above-mentioned samples were detected by HI, Dot-ELISA and RT-PCR methods. The results in- dicated that aerosols were isolated from the 4 days to the 43 days after inoculation. It was proved that H9N2 subtype AIV could copy themselves in respiratory passage and cloaca, and then could formation of aerosols. AIV H9N2 subtype could be isolated from cloacal and tracheal swabs 3 days after inoculation and lasted for 45 days, viruses were detected from all infected SPF chickens on 7 days.
3.Screening of Poly-?-glutamic Acid High Productive Strain and Optimization of Fermentation Medium
Xue-Chao WU ; Xin-Jiang CAO ; Zhi-Xia JI ; Shou-Wen CHEN ;
Microbiology 2008;0(10):-
Bacillus subtilis B6-1 was used as an original strain for mutagenic treatment and a defined medium was used as the selective medium. A mutant named B. subtilis W003 was isolated after three serial ultraviolet (UV) irradiations and one diethyl sulfate (DES) treatment. The ?-PGA yield on a rotary shaker was enhanced from 10.9 g/L in parental strain to 20.5 g/L in the mutant. It was illustrated by single factor experiments that the optimal carbon and nitrogen sources were glucose and (NH4)2SO4 respectively. The optimal fermentation medium was achieved by orthogonal test. In the optimal medium, a ?-PGA yield of 45.3 g/L was obtained after 36 h cultivation.
4.Experience and thinking on establishing fine course of oral and maxillofacial surgery
lian, GUO ; zhi-yuan, ZHANG ; jia-wei, ZHENG ; xia, CAO ; yuan-jin, XU ; chi, YANG
Journal of Shanghai Jiaotong University(Medical Science) 2008;0(S1):-
Objective To explore the practical ways on establishing fine course of oral and maxillofacial surgery effectively. Methods Relying on the advantages of the discipline,great efforts had been made in step-by-step enhancement of the quality of teachers,teaching contents,teaching methods and administration. Results Through the establishing of fine course,we could improve the curriculum system,enhance the force of education team,and improve the quality of education. Conclusion Establishing fine course of oral and maxillofacial surgery depends on the environment of sharing educational resources,adjusting the curriculum system and establishing an excellent educational team.
5.Clinical observation on moxibustion therapy plus tuina in treating children with recurrent respiratory tract infections due to qi deficiency of spleen and lung
Yun XIA ; Zhi-Liang CAO ; Ying-Han LIU ; Bi-Dan LOU ; Wei ZHANG ; Fu-Qing ZHANG
Journal of Acupuncture and Tuina Science 2021;19(5):371-377
Objective: To observe the clinical efficacy of moxibustion therapy plus Liu's pediatric massage (tuina) for children with recurrent respiratory tract infections due to qi deficiency of spleen and lung. Methods: A total of 60 children who met the inclusion criteria were divided into an observation group and a control group according to the visiting sequence, with 30 cases in each group. Children in the observation group were treated with moxibustion therapy plus Liu's pediatric massage, and those in the control group were treated with Liu's pediatric massage alone. The incidence of respiratory tract infections and traditional Chinese medicine (TCM) symptoms score were observed and recorded in both groups before and after treatment. And the clinical efficacy was compared between the two groups. Results: The total effective rate of the observation group was 93.3%, and that of the control group was 83.3%. The difference between the two groups was statistically significant (P<0.05). After treatment, the TCM symptoms score and total times of infections in both groups were all statistically different from those before treatment (all P<0.05). The differences in TCM symptoms score and infection frequency before and after treatment in the observation group were statistically different from those in the control group (both P<0.05). Conclusion: Moxibustion therapy plus Liu's pediatric massage has a better effect in improving the clinical symptoms and reducing the frequency of respiratory tract infections for children with recurrent respiratory tract infections due to qi deficiency of spleen and lung than the pediatric massage alone.
6.Stable cell line for secretion of replication-defective hepatitis B virus vector expressing blasticidin resistant gene
Jin-Xia LIU ; Dian-Xing SUN ; Zhi-Chen CAO
Chinese Journal of Experimental and Clinical Virology 2009;23(4):316-318
Objective To construct a stable cell line with permanent secretion of recombinant hepatitis B virus(HBV) vector, which express blasticidin resistant gene. Methods Replication-defective HBV vector, pCH-BsdR, which express blasticidin resistance gnne was constructed by deleting the HBV genes and inserting the blasticidin resistance gene into the S region. The CA18-resistant, the packaging signal deleted HBV helper plasmid, pcDNA3.1-CH3142, and the HBV vector pCH-BsdR were cotransfectcd into HepG2 cells. Cell clones were selected by the adding of both blasticidin and G418, then serial detection were done.Results After 36 cell clones were picked and expanded. Three cell clones were defined as the best. Quantity of their HBV DNA were 4.1 × 106, 3.6×106 and 1.2× 106 copies/ml, respectively. Enveloped recombinant, but not wild type HBV were confirmed in the culture medium. Conclusions The stable cell lines can realize large preparation of recombinant HBV virions. This will contribute to the use of HBV vector for gene therapy and HBV suseeptihle cell lines screening.
7.Monoclonal antibody: the corner stone of modern biotherapeutics.
Zhi-nan XIA ; Xue-ting CAI ; Peng CAO
Acta Pharmaceutica Sinica 2012;47(10):1275-1280
Worldwide sales of biologic drugs exceeded 100 billion USD in 2011. About 32% is from therapeutic monoclonal antibody (mAb). With many blockbuster biopharmaceutical patents expiring over the next decade, there is a great opportunity for biosimilar to enter the worldwide especially emerging market. Both European Medicines Agency (EMA) and Food and Drug Administration (FDA) have introduced regulatory frameworks for the potential approval of biosimilar mAb therapeutics. Rather than providing a highly abbreviated path, as in the case for small molecule chemical drug, approval for biosimilar mAb will require clinical trial and the details will be very much on a case-by-case basis. Since mAb is the dominant category of biologic drugs, mAb will be the focus of this review. First, the United States (US) and European Union (EU) approved mAb and those in phase 3 trials will be reviewed, then strategies on how to win biosimilar competition will be reviewed.
Animals
;
Antibodies, Bispecific
;
therapeutic use
;
Antibodies, Monoclonal
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Biosimilar Pharmaceuticals
;
standards
;
Clinical Trials, Phase III as Topic
;
Drug Approval
;
European Union
;
Humans
;
United States
;
United States Food and Drug Administration
9.Effects of genistein on expression of TGF-beta1 and intracellular free Ca2+ concentration in fibroblasts derived from human hypertrophic scar.
Chuan CAO ; Shi-Rong LI ; Xia DAI ; Zhi FENG ; Shan XIA ; Yan-Qing CHEN ; Heng YAO
Chinese Journal of Plastic Surgery 2008;24(5):335-338
OBJECTIVETo observe the effects of Genistein on TGF-beta1 expression and the intracellular free Ca2+ concentration in human hypertrophic scar fibroblasts, and to discuss the mechanism of the anti-fibrosis effect.
METHODSFibroblasts were derived from human hypertrophic scar tissue and cultured in vitro. Genistein in different concentrations (25, 50, 100 micromol/L) was administrated to the fibroblasts, respectively. After 48 hours of co-culture, the expression of TGF-beta1 mRNA and protein were examined by RT-PCR and Western-Blot assay respectively. The intracellular free Ca2+ concentration in hypertrophic scar fibroblasts pretreated by Genistein was determined by laser confocal scanning microscopy with or without the stimulation of bFGF.
RESULTSGenistein inhibited the expression of TGF-beta1 in hypertrophic scar fibroblasts on a concentration-dependent manner. bFGF significantly elevated the intracellular free Ca2+ concentration, however its stimulating effect was remarkably alleviated when the fibroblasts were pre-treated by Genistein.
CONCLUSIONSGenistein can reduce the expression of TGF-beta1 and block the accumulation of intracellular free calcium induced by growth factors. It maybe one of the possible mechanisms of Genistein's antifibrosis effect.
Calcium ; analysis ; Cells, Cultured ; Cicatrix, Hypertrophic ; metabolism ; Fibroblasts ; drug effects ; metabolism ; Genistein ; pharmacology ; Humans ; Transforming Growth Factor beta1 ; metabolism